(RTTNews) - Sandoz, Inc., an unit of Novartis Pharma AG, is recalling one lot of deep vein thrombosis (DVT) medication Enoxaparin Sodium in the form of injection for the potential exposure to high ...

Patients exposed to a higher dose may be subject to bleeding complications. Apotex Corp announced the voluntary recall of 2 batches of Enoxaparin Sodium Injection ...

Syringe marking errors, which can lead to incorrect dosing, caused a recall of Enoxaparin Sodium Injection, a generic version of blood clot medication Lovenox. The recall issued Tuesday by Apotex, a ...

Princeton, NJ, Sandoz Inc. (“Sandoz”) is initiating a recall of one lot (SAB06761A, Exp 04/2023) of Enoxaparin Sodium Injection, USP 40 mg/0.4 mL Single-Dose Syringes to the consumer level. A portion ...

The prophylaxis of thromboembolic disorders (deep vein thrombosis) in patients undergoing: orthopedic surgery of the hip or knee; high-risk abdominal, gynecological, or urological surgeries; ...

The U.S. Food and Drug Administration today approved the first generic version of Lovenox (enoxaparin sodium injection), an anti-coagulant drug used to prevent deep vein thrombosis (DVT), a ...

Princeton, New Jersey, April 25, 2012 – Sandoz today announced the introduction of enoxaparin sodium injection, USP 3 mL vials, a generic version of Sanofi's Lovenox® Injection Multiple-Dose Vials, in ...

The FDA has approved Amphastar Pharmaceuticals' Abbreviated New Drug Application (“ANDA”) for Enoxaparin Sodium Injection 300mg/3mL (100mg/mL) Multiple Dose Vial (MDV). The Company plans to launch ...

July 26, 2010 — The US Food and Drug Administration (FDA) has approved the first generic formulation of enoxaparin sodium injection (Sandoz, Inc; brand name, Lovenox; Sanofi-Aventis US, LLC), a ...

Silver Spring, MD - The US Food and Drug Administration (FDA) has granted approval of the first generic formulation of enoxaparin (Lovenox, Sanofi-Aventis) sodium injection, a low-molecular-weight ...